Alliance Global Partners analyst Ben Haynor downgraded Viveve Medical to Neutral from Buy and dropped coverage of the name after the company announced the pivotal PURSUIT trial in stress urinary incontinence in women did not meet its primary endpoint nor several secondary endpoints. The analyst expects little interest from potential acquirers and sees little upside for shareholders.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIVE: